Prognostic Significance of Platelet Recovery in Myelodysplastic Syndromes With Severe Thrombocytopenia
Open Access
- 8 October 2018
- journal article
- research article
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 24 (9_suppl) , 217S-222S
Abstract
Severe thrombocytopenia is a serious condition that frequently arises in patients with myelodysplastic syndrome (MDS) and is associated with poor prognosis. Few studies have investigated the prognostic significance of platelet recovery in patients with MDS having thrombocytopenia. We retrospectively analyzed 117 patients with de novo MDS complicated with thrombocytopenia (platelet count [PLT] < 100 × 109/L). Patients received decitabine treatment (schedule A) or decitabine followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT; schedule B). Severe thrombocytopenia (PLT < 20 × 109/L), identified in 31 (26.5%) patients, was associated with poor survival. The PLT increased significantly after decitabine treatment in the 2 groups. Patients with thrombocytopenia treated with schedule B showed a superior prognosis compared to those treated with schedule A. On analysis of overall survival by platelet response in patients with severe thrombocytopenia, a significant survival advantage was observed in patients who achieved a platelet response, who would further benefit from allo-HSCT following decitabine therapy. The results indicate a potentially favorable prognostic impact of platelet response achieved with decitabine. Patients with MDS having severe thrombocytopenia may benefit from the effective recovery of platelets and further allo-HSCT following decitabine therapy.Keywords
Funding Information
- Jiangsu Provincial Special Program of Medical Science (BL2012005)
This publication has 20 references indexed in Scilit:
- Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?Best Practice & Research Clinical Haematology, 2012
- The effect of decitabine on megakaryocyte maturation and platelet releaseThrombosis and Haemostasis, 2011
- Thrombocytopenia in Myelodysplastic Syndromes and MyelofibrosisSeminars in Hematology, 2009
- Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician SurveysJNCI: Journal of the National Cancer Institute, 2008
- Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemCancer, 2008
- A prognostic score for patients with lower risk myelodysplastic syndromeLeukemia, 2007
- The incidence and impact of thrombocytopenia in myelodysplastic syndromesCancer, 2007
- Myelodysplastic Syndromes — Coping with Ineffective HematopoiesisNew England Journal of Medicine, 2005
- The effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromesLeukemia Research, 2004
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003